肝细胞癌的预后及免疫治疗反应预测：非组蛋白乙酰化/去乙酰化评分的作用

Prognostic and immunotherapeutic response prediction in hepatocellular carcinoma: role of non-histone acetylation/deacetylation scoring.

作者信息

Li Jizhen, Huang Sisi, Yuan Fangling, Yang Xunjun, Xie Qipeng

机构信息

Department of Clinical Laboratory, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China.

Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

出版信息

Discov Oncol. 2025 Aug 7;16(1):1488. doi: 10.1007/s12672-025-03339-9.

DOI:10.1007/s12672-025-03339-9

PMID:40773148

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12332175/

Abstract

BACKGROUND

Post-translational modification is crucial, with acetylation and deacetylation enzymes playing important roles. Their roles in liver cancer, however, remain unclear.

METHODS

In this study, a KAT + KDAC score was developed to assess the prognosis and response to immunotherapy in liver cancer patients. The association of HDAC1, HDAC2, and HDAC3 with patient prognosis was analyzed, and the PPI network was constructed. The correlation between the score and P53 mutation status, stage, and TNM staging was also investigated. Additionally, the response to chemotherapy was evaluated. The TIDE score was also assessed.

RESULTS

Our analysis showed that HDAC1, HDAC2, and HDAC3 are highly associated with patient prognosis and are centrally located in the PPI network. Patients with high KAT + KDAC scores had a better prognosis, and the score correlated with P53 mutation status, stage, and TNM staging. Notably, patients with low KAT + KDAC scores demonstrate resistance to cisplatin and gemcitabine, and have a lower TIDE score. Moreover, the KAT + KDAC score accurately predicted patient response to immunotherapy.

CONCLUSION

The KAT + KDAC modification pattern is critical in the initiation and progression of liver cancer. This score can be used to predict patient prognosis and immunotherapy response. Future studies are needed to further explore the underlying mechanisms and potential therapeutic applications.

摘要

背景

翻译后修饰至关重要，乙酰化和去乙酰化酶发挥着重要作用。然而，它们在肝癌中的作用仍不清楚。

方法

在本研究中，开发了一种KAT+KDAC评分来评估肝癌患者的预后和对免疫治疗的反应。分析了HDAC1、HDAC2和HDAC3与患者预后的关联，并构建了蛋白质-蛋白质相互作用（PPI）网络。还研究了该评分与P53突变状态、分期和TNM分期之间的相关性。此外，评估了对化疗的反应。还评估了TIDE评分。

结果

我们的分析表明，HDAC1、HDAC2和HDAC3与患者预后高度相关，且位于PPI网络的中心位置。KAT+KDAC评分高的患者预后较好，该评分与P53突变状态、分期和TNM分期相关。值得注意的是，KAT+KDAC评分低的患者对顺铂和吉西他滨耐药，且TIDE评分较低。此外，KAT+KDAC评分准确预测了患者对免疫治疗的反应。